Monday, March 18, 2013

Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy




AIDS:
12 April 2002 - Volume 16 - Issue 6 - pp 934-937
Research Letters

Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy

Collazos, Julio; Martinez, Eduardo; Mayo, José; Ibarra, Sofia

Free Access
Article Outline
Collapse Box

Author Information

Section of Infectious Diseases, Hospital de Galdakao, Vizcaya, Spain.
Received: 3 August 2001;
revised: 16 November 2001; accepted: 26 November 2001.
A total of 351 determinations of sexual hormones were carried out in 189 HIV-infected men in stable clinical condition. Highly active antiretroviral therapy (HAART) was associated with increased levels of both testosterone and 17β-estradiol, but not with luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Protease inhibitors were more associated with testosterone, and non-nucleoside reverse transcriptase inhibitors with 17β-estradiol. The values of both hormones, but not those of LH and FSH, increased with respect to pre-treatment levels in those patients who initiated HAART.

More Information


Higher estradiol in HIV has been associated with gynecomastia (breast enlargement) in a minority of men on non-nucleoside analog HIV medications:
HIV medication induced gynecomastia

Thursday, March 14, 2013

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)



All of the presentations in this section were great.

The one on new drugs is contained in the last set of slides (blue slides at 1:22:46)


http://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo


For individual reports on each drug (Thanks to Natap.org):


NEW HIV DRUGS at CROI












Monday, March 04, 2013

"Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth




NATAP http://natap.org/
_______________________________________________

"Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth

20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta

Mark Mascolini

An HIV-infected US infant treated from 30 hour after birth had no detectable viral load, no detectable HIV DNA in blood cells, and no HIV-specific antibodies at 26 months of age on standard tests, even though antiretroviral therapy (ART) stopped at age 18 months [1]. Deborah Persaud (Johns Hopkins University) and colleagues believe their findings confirm "a state of functional HIV cure."

Speedy treatment after birth appeared to work like postexposure prophylaxis (PEP), stopping HIV from getting a foothold in this baby's body and establishing a latent viral reservoir. Evidence that the baby was infected persisted, however, in vanishingly small levels of HIV RNA and HIV DNA detectable in blood and cells. But the researchers do not believe these viral traces can reestablish active infection.

US HIV experts including Daniel Kuritzkes (Harvard) and Steven Deeks (University of California, San Francisco) are reserving judgment on whether the child had established HIV infection, the New York Times reports [2]. "The one uncertainty is really definitive evidence that the child was indeed infected," Kuritzkes told the Times.

Persaud and colleagues believe their findings show the infant did have HIV infection--though perhaps not an established latent reservoir. "For pediatrics, this is our Timothy Brown," Persaud told the Times, referring to the "Berlin patient" cured of HIV after bone marrow transplantation from a donor with cells resistant to HIV.

The researchers confirmed exposure to HIV by checking maternal HIV antibody and plasma HIV RNA tests, including HIV resistance testing. The baby appeared to be infected with wild-type (nonmutant) HIV-1 subtype B. Persaud and coworkers believe they documented HIV infection in the infant through standard HIV DNA polymerase chain reaction and plasma HIV RNA testing. Positive HIV DNA and HIV RNA testing on separate infant blood samples collected on the second day of life showed that the child carried HIV that was genetically matched to the mother's virus. Plasma viral load at that point was around 20,000 copies [2], relatively low for an infant.

Three-drug treatment of the Mississippi infant began within 30 hours of birth and continued to the age of 18 months. Plasma HIV RNA tests remained positive on days 7, 12, and 20, then became undetectable at age 29 days. From 1 through 26 months, plasma HIV RNA remained below the detection limit of a 20-copy assay repeated 16 times.

Clinicians stopped antiretroviral therapy at age 18 months. Ultrasensitive assays detected a single copy of HIV RNA at age 24 months and 37 copies of HIV DNA per million peripheral blood mononuclear cells (PBMCs) enriched for monocytes. Samples yielded no evidence of replication-competent HIV after coculture of 22 million purified resting CD4 cells.

When the infant was 26 months old, an ultrasensitive assay spotted 4 HIV DNA copies per million PBMCs but no 2-LTR circles (which indicate that HIV genetic material is being imported into the nucleus of an infected cell). Standard clinical assays remain negative for HIV RNA, PBMC HIV DNA, and HIV-specific antibodies.

"This is the first well-documented case of functional cure in an HIV-positive child," Persaud and colleagues maintain. The case, they believe, "suggests that very early ART may prevent establishment of a latent reservoir and achieve cure in children."

The child is now 2.5 years old and has not taken antiretrovirals for a year.

References
1. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 48LB.
2. Pollack A, McNeil DG Jr. In medical first, a baby with H.I.V. is deemed cured. New York Times. March 4, 2013.http://www.nytimes.com/2013/03/04/health/for-first-time-baby-cured-of-hiv-doctors-say.html.

Is the End of AIDS in Sight?



Reality Check: Is the End of AIDS in Sight?

Dr Francois Dabis from the Bordeaux School of Public  Health at the University of  Bordeaux (Segalen, France) gave an excellent talk today at CROI-2013 that is easily understood by any lay person who wants to know how far we have come in HIV and the challenges ahead



CLICK HERE TO WATCH PRESENTATION

Tuesday, February 05, 2013

GSK - ViiV Abandons Lersivirine - An Investigational NNRTI HIV Medication



Dear HIV Community Writer,

ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine.  This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that offer improvement over current options. 

After much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class, and that R&D resources for ViiV Healthcare should prioritize efforts to identify compounds that further HIV treatment.

We remain committed to exploring candidates that will advance HIV treatment and contribute to improving outcomes for people living with HIV.

Please don’t hesitate to reach out to me directly if you have any questions regarding this announcement.

Kind regards,



Marc Meachem | Director, External Affairs

Monday, February 04, 2013

Successful treatment is "as effective as consistent condom use" in reducing HIV transmission


At least, for vaginal sex...(no data on anal sex!)

The statement notes that there is now conclusive randomised clinical trial evidence, from the HPTN 052 trial, to show that transmission of HIV through vaginal sex is significantly reduced when an HIV-positive person is taking effective antiretroviral therapy (ART). In this trial, early treatment reduced HIV transmission to an uninfected partner by 96%.


Position statement on the use of antiretroviral therapy to reduce HIV transmission January 2013. The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS

Recent Studies Show Concerns With The Use of Tenofovir (Viread), Popular Drug in HIV Treatment



Tenofovir impairs enzyme that stops cells aging


This study let us know that NRTI drugs, already known for causing the damage to mitochondrial DNA that leads to peripheral neuropathy, fat loss and some other side-effects, also exert an effect on cellular DNA, and that in this case tenofovir may be the drug to keep an eye on.

Telomerase shortening is, by definition, a side-effect that won’t start causing symptoms for many years, and the study does provide a cautionary note in discussions about the possibility of very long-term side-effects associated with the use of tenofovir, both in HIV treatment and in pre-exposure prophylaxis.

More information here


************************************************************************************************************************************************

Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir+Lamivudine or Tenofovir DF+ Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202


"In conclusion, we have shown significant perturbation in mitochondrial indices after 96 weeks of nonthymidine NRTI containing regimens which were assigned randomly. In the TDF/FTC group, changes in oxidative phosphorylation complex I and complex IV activity levels consistently were inversely correlated with changes in several objective measures of body fat, including in both subcutaneous and visceral compartments"


  Patients with human immunodeficiency virus type 1 (HIV-1) infection receiving thymidine nucleoside reverse-transcriptase inhibitors (NRTIs) experience a high rate of metabolic abnormalities, including lipoatrophy. Depletion of adipose tissue mitochondrial DNA (mtDNA) and impairment of the oxidative phosphorylation system are associated with lipoatrophy induced by thymidine NRTI containing regimens. Mitochondrial oxidative phosphorylation enzymes nicotinamide adenine dinucleotide (reduced; NADH) dehydrogenase (complex I) and cytochrome c oxidase (complex IV) contain polypeptides of mtDNA-encoded subunits and so are affected by mtDNA depletion.
In the current era of nonthymidine NRTI containing regimens, lipoatrophy incidence has significantly decreased but has not been completely prevented . In addition, subjects who have established lipoatrophy while taking thymidine NRTI containing regimens experience only a slow and incomplete resolution of lipoatrophy after switching to nonthymidine NRTI based therapy , putting into question the mitochondrial toxicity.

More information here

************************************************************************************************************************************************

Fortunately, 10 year observational data on the use of TDF show encouraging results in stabilization of reduced creatinine clearance


Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up


 "In this cohort, TDF exposure was associated with reduced kidney function, but the loss in eGFR attributable to TDF is relatively mild in a long-term perspective.

There has been debate about the association between TDF exposure and renal dysfunction and about the clinical impact of the loss in eGFR due to TDF exposure. Our study shows that the association was not of a high magnitude and that the quantified loss in eGFR attributable to TDF is relatively modest after many years of exposure. Importantly, the loss attributable to TDF seems to occur during the first year of exposure and stabilizes after that. Although the loss is maintained, it does not seem to further deteriorate with additional years of exposure. The clinical impact of this association need to be analyzed, taking into account the efficacy of TDF, but it is highly plausible that TDF exposure, although associated with reduced kidney function, has no severe adverse effects over the long term for most HIV-positive patients.”

More information here

Support PoWeR

Program For Wellness Restoration

Health News

Blog Archive

The Cure of HIV is Possible in Our Lifetime